Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.


Aspirin, a medicine that reduces platelet activity, is recommended for people with diabetes who already have heart disease in order to reduce their likelihood of having a further heart attack or stroke. Whether aspirin reduces the risk of a first heart attack or a first stroke in people with diabetes is unclear.

This study, conducted in people with diabetes who did not have heart disease, compared the ability of aspirin 100 mg once daily, aspirin 200 mg once daily or aspirin 100 mg twice daily to reduce platelet activity.


Double-blind, randomised, three-way cross-over, interventional clinical trial.



Aspirin 100mg twice-daily reduced platelet reactivity more effectively than 100mg once-daily, and numerically more than 200mg once-daily. Clinical outcome trials evaluating primary cardiovascular prevention with aspirin may need to consider using more frequent doses. The published results are available here.